-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Bicara Therapeutics, Lowers Price Target to $24

Benzinga·10/29/2026 14:48:36
語音播報
Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and lowers the price target from $33 to $24.